Combat Cancer, Author at Combat Group

A history of hyperthermia therapy (part I)

by Combat Cancer | Jan 22, 2023 | Hyperthermia, Uncategorized

In the first of three articles exploring the history of hyperthermia as a medical treatment, Johannesburg-based urologist Dr Steven Cornish delves back into antiquity to its origins and explores developments including thermal therapy combined with radiotherapy and...

Short-term use of HIVEC in intermediate risk bladder-cancer patients is non-inferior to classical treatments and longer-term use shows great promise in Spanish trial

by Combat Cancer | Dec 1, 2022 | Uncategorized

Press release, 1 December 2022 Combat Medical is pleased to announce the results of the HIVEC I phase 3 randomised controlled trial, published in European Urology Oncology on 23 November 2022. As with this year’s HIVEC II publication, this short-term regimen shows...

“If we could kill the tumour without radical surgery, boy would that be a boon for patients. And I think that’s where we are headed”

by Combat Cancer | Aug 23, 2022 | Uncategorized

The Medical Innovators Interview with Professor Brant Inman | July 2022 From superheated nanoparticles to intravesical therapy and barriers to change in bladder-cancer treatment – there’s plenty of food for thought in our July Medical Innovators interview, with...

Growing data points towards use of HIVEC® in high-risk and BCG-unresponsive patients following publication of HIVEC® bladder cancer RCT results

by Combat Cancer | Aug 22, 2022 | Uncategorized

Press release, 22 August 2022 Combat Medical is pleased to announce the results of the HIVEC® II trial, published in European Urology on 20 August 20221. It is one in a series of recent HIVEC® publications helping chemo-hyperthermia to find its place in the treatment...

“There’s a new vitality in bladder cancer. And it’s exciting to have come through 20 years of agony and start to see the fruits of all that labour”

by Combat Cancer | Aug 16, 2022 | Uncategorized

The Medical Innovators Interview with Professor Michael O’Donnell | June 2022 Gem/doce vs BCG, quantum dots and the future of uro-oncology come under the microscope in our June Medical Innovators Interview, with Combat Medical’s Guy Cooper in conversation...

« Older Entries

A history of hyperthermia therapy (part I)

Short-term use of HIVEC in intermediate risk bladder-cancer patients is non-inferior to classical treatments and longer-term use shows great promise in Spanish trial

“If we could kill the tumour without radical surgery, boy would that be a boon for patients. And I think that’s where we are headed”

Growing data points towards use of HIVEC® in high-risk and BCG-unresponsive patients following publication of HIVEC® bladder cancer RCT results

“There’s a new vitality in bladder cancer. And it’s exciting to have come through 20 years of agony and start to see the fruits of all that labour”

Recent Posts

Recent Comments

Archives

Categories

Meta